Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526071 · ClinicalTrials.gov registry record · Phase 2
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
A Phase 2 study, sponsored by Amicus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00526071 is a Phase 2 study that was terminated before completion, run by Amicus Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT00526071, a Phase 2 study, was terminated before completion, sponsored by Amicus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
Interventions
- DRUG migalastat HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-09-17 |
| Est. Completion | 2012-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00526071
The ClinicalTrials.gov registry entry for NCT00526071 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which migalastat HCl is the first listed.
NCT00526071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00526071 about?
NCT00526071 is a clinical study titled "Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study". Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
What is the current status of trial NCT00526071?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2007-09-17. Estimated completion is 2012-09-08.
What interventions are being tested in trial NCT00526071?
The interventions under investigation include: migalastat HCl (DRUG).
Who is sponsoring clinical trial NCT00526071?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.